Compound 2234

Identifiers

Canonical SMILES:

COc1cc(CNC(=O)c2ccc(F)c(CNC3=NCCN3)c2)cc(OC)c1

IUPAC name:

3-{[(4,5-dihydro-1H-imidazol-2-yl)amino]methyl}-N-[(3,5-dimethoxyphenyl)methyl]-4-fluorobenzamide

InChi:

InChI=1S/C20H23FN4O3/c1-27-16-7-13(8-17(10-16)28-2)11-24-19(26)14-3-4-18(21)15(9-14)12-25-20-22-5-6-23-20/h3-4,7-10H,5-6,11-12H2,1-2H3,(H,24,26)(H2,22,23,25)

InChiKey:
```
VDAMWMOTTUWVPR-UHFFFAOYSA-N
```

External links

138753248

CHEMBL5172311

HLS

External search

Bibliography (1)

Publication	Name
Aho Erin R., Wang Jing, Gogliotti Rocco D., Howard Gregory C., Phan Jason, Acharya Pankaj, Macdonald Jonathan D., Cheng Ken, Lorey Shelly L., Lu Bin, Wenzel Sabine, Foshage Audra M., Alvarado Joseph, Wang Feng, Shaw J. Grace, Zhao Bin, Weissmiller April M., Thomas Lance R., Vakoc Christopher R., Hall Matthew D., Hiebert Scott W., Liu Qi, Stauffer Shaun R., Fesik Stephen W., Tansey William P.. . Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity Cell Reports.	C3

Publication

Name

Aho Erin R., Wang Jing, Gogliotti Rocco D., Howard Gregory C., Phan Jason, Acharya Pankaj, Macdonald Jonathan D., Cheng Ken, Lorey Shelly L., Lu Bin, Wenzel Sabine, Foshage Audra M., Alvarado Joseph, Wang Feng, Shaw J. Grace, Zhao Bin, Weissmiller April M., Thomas Lance R., Vakoc Christopher R., Hall Matthew D., Hiebert Scott W., Liu Qi, Stauffer Shaun R., Fesik Stephen W., Tansey William P.. . Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity Cell Reports.

Pharmacological data

Biochemical tests	Cellular tests	PK tests	Cytotoxicity tests
4	2	0	0

Targets

PPI family	Best activity	Diseases	MMoA
WDR5/MLL	9.10	Leukemia	Inhibition

Physicochemical filters

Descriptor	Lipinski's RO5	Veber	Pfizer's 3/75
MW	≤ 500 g/mol	-	-
AlogP	≤ 5	-	≤ 3
HBA	≤ 10	-	-
HBD	≤ 5	-	-
(HBA + HBD)	-	≤ 12	-
TPSA	-	≤ 140 Å²	≥ 75 Å²
RB	-	≤ 10	-

	Descriptor	Lipinski's RO5	Veber	Pfizer's 3/75
Compliance
MW	386.18 g/mol
HBA	7
HBD	3
HBA + HBD	10
AlogP	1.72
TPSA	85.59
RB	7

Radar chart

Short name	Threshold
MW	≤ 500 g/mol
AlogP	≤ 5
HBD	≤ 5
HBA	≤ 10
TPSA	≤ 140 Å²
RB	≤ 10
ArRing	≤ 4
Fsp3	≥ 0.4
R/S	≥ 1

PCA : iPPI-DB chemical space

PCA : Correlation circle

Efficiencies: iPPI-DB biplot LE versus LLE

Summary

Bibliographic ressources	Biochemical tests	Cellular tests	PK tests	Cytotoxicity tests
1	4	2	0	0

Pharmacological data

Bibliography	Name	Target	Competition	Assay type	Assay name	Cell line	Activity type	Activity
10.1016/j.celrep.2019.02.047	C3	KMT2A Q03164	WDR5 P61964	Biochemical assay	Surface Plasmon Resonance		pKd (dissociation constant, -log10)	9.10
10.1016/j.celrep.2019.02.047	C3	KMT2A Q03164	WDR5 P61964	Cellular assay	CETSA MV4-11	MV4-11	pEC50 (half maximal effective concentration, -log10)	5.60
10.1016/j.celrep.2019.02.047	C3	KMT2A Q03164	WDR5 P61964	Cellular assay	CETSA K562	K562	pEC50 (half maximal effective concentration, -log10)	5.54
10.1016/j.celrep.2019.02.047	C3	KMT2A Q03164	WDR5 P61964	Biochemical assay	Fluorescence Polarization 10mer-Thr-FAM		pKi (inhibition constant, -log10)	7.99
10.1016/j.celrep.2019.02.047	C3	KMT2A Q03164	WDR5 P61964	Biochemical assay	Time-Resolved FRET		pKi (inhibition constant, -log10)	8.90
10.1016/j.celrep.2019.02.047	C3	KMT2A Q03164	WDR5 P61964	Biochemical assay	HMT MLL1		pIC50 (half maximal inhibitory concentration, -log10)	6.76

Ta	Name	Drugbank ID
0.4531	Trimethobenzamide	DB00662
0.4485	Pimavanserin	DB05316
0.4397	Etamivan	DB08989
0.4275	Troxipide	DB13419
0.4219	Itopride	DB04924
0.4172	(2S)-2-{3-[({[2-fluoro-4-(trifluoromethyl)phenyl]carbonyl}amino)methyl]-4-methoxybenzyl}butanoic acid	DB07070
0.4148	Lomerizine	DB14065
0.4122	Vestipitant	DB11949
0.4056	LY-2456302	DB12341
0.4048	Aniracetam	DB04599
0.4043	Picotamide	DB13327
0.3986	PF-04418948	DB12024
0.3954	Nonivamide	DB11324
0.3952	Flufenoxuron	DB15006
0.3938	N-(2-CHLORO-4-FLUOROBENZOYL)-N'-(5-HYDROXY-2-METHOXYPHENYL)UREA	DB07968